Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2024

Summarizes the Valuation of the Company’s Financial Instruments

The following summarizes the valuation of the Company’s financial instruments (in thousands). The tables do not include either cash on hand or assets and liabilities that are measured at historical cost or any basis other than fair value.


	As of June 30, 2024
	Level 1		Level 2		Total
Cash equivalents:
Money market funds	$	15,857	$	—	$	15,857
Total cash equivalents	$	15,857	$	—	$	15,857


	As of December 31, 2023
	Level 1		Level 2		Total
Cash equivalents:
Money market funds	$	34,741	$	—	$	34,741
Total cash equivalents	$	34,741	$	—	$	34,741

Short-term investments:
U.S. government and agency securities	—		999		999
Total short-term investments	$	—	$	999	$	999

Total	$	34,741	$	999	$	35,740

The following table summarizes the Company's available-for-sale securities by security type:


	As of June 30, 2024
	Amortized Cost		Unrealized Losses		Fair Value
Cash equivalents:
Money market funds	$	15,857	$	—	$	15,857
Total cash equivalents	$	15,857	$	—	$	15,857


	As of December 31, 2023
	Amortized Cost		Unrealized Losses		Fair Value
Cash equivalents:
Money market funds	$	34,741	$	—	$	34,741
Total cash equivalents	$	34,741	$	—	$	34,741

Short-term investments:
U.S. government and agency securities	999		—		999
Total short-term investments	$	999	$	—	$	999

Total	$	35,740	$	—	$	35,740

LUMOS PHARMA, INC. 10-Q